

A 62-year-old woman with multiple recurrent lumbar and sacral cord HBs. She was treated with [anlotinib](#) (8mg qd d1-14, q3w) for three months and her follow up radiological examination demonstrated marked tumor regression which was evaluated as having partial response pursuant to RECIST 1.1 system. She is currently still receiving treatment of anlotinib orally and the lesions continuously reduced.

Anlotinib can cause significant radiographic response in a patient with multiple recurrent lumbar and sacral cord HBs for the first time. This might enable a novel therapeutic approach for patients with multiple recurrent HB or those with multiple lesions such as in VHL disease which are difficult to resect surgically ¹⁾.

¹⁾

Jin N, Sun C, Hua Y, Wu X, Li W, Yin Y. Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report. Front Oncol. 2022 Apr 27;12:859157. doi: 10.3389/fonc.2022.859157. PMID: 35574394; PMCID: PMC9092942.

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

<https://neurosurgerywiki.com/wiki/doku.php?id=anlotinib>

Last update: **2024/06/07 02:53**

